Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 10/2015

01.10.2015 | Educational Review

Primary hyperoxalurias: diagnosis and treatment

verfasst von: Efrat Ben-Shalom, Yaacov Frishberg

Erschienen in: Pediatric Nephrology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Primary hyperoxalurias (PH) comprise a group of three distinct metabolic diseases caused by derangement of glyoxylate metabolism in the liver. Recent years have seen advances in several aspects of PH research. This paper reviews current knowledge of the genetic and biochemical basis of PH, the specific epidemiology and clinical presentation of each type, and therapeutic approaches in different disease stages. Potential future specific therapies are discussed.
Literatur
1.
Lepoutre C (1925) Calculs multiples chez un enfent: Infiltration du parenchyme renal par des depots crystallins. J Urol 20:424
2.
3.
Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 123:236–246PubMedCentralPubMedCrossRef
4.
Schepers MS, Van Ballegooijen ES, Bangma CH, Verkoelen CF (2005) Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int 68:1543–1553PubMedCrossRef
5.
Schepers MS, Van Ballegooijen ES, Bangma CH, Verkoelen CF (2005) Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. Kidney Int 68:1660–1669PubMedCrossRef
6.
Van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA (2003) Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 18:273–279PubMedCrossRef
7.
Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS (2005) International registry for primary hyperoxaluria. Am J Nephrol 25:290–296PubMedCrossRef
8.
Van der Hoeven SM, van Woerden CS, Groothoff JW (2012) Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant 27:3855–3862PubMedCrossRef
9.
Kopp N, Leumann E (1995) Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 10:2224–2227PubMed
10.
Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N (1995) Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant 10:3–7PubMedCrossRef
11.
Harambat J, Van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, (ESPN/ERA-EDTA) (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458–465PubMedCentralPubMedCrossRef
12.
Fisher D, Hiller N, Drukker A (1995) Oxalosis of bone: report of four cases and a new radiological staging. Pediatr Radiol 25:293–295PubMedCrossRef
13.
Guerra EN, Vianna L, Sobreira MN, de Araújo FN, de Melo NSJ (2012) Oral manifestations of hyperoxaluria. Craniofac Surg 22:2191–2192CrossRef
14.
Frishberg Y, Feinstein S, Rinat C, Drukker A (2000) Hypothyroidism in primary hyperoxaluria type 1. J Pediatr 136:255–257PubMedCrossRef
15.
Jorge P, García González MJ, Rebollo SG, García S, Bosa F, Laynez I, De la Rosa A (2013) Myocardial infiltration by oxalate: a rare case of cardiomyopathy by accumulation of oxalate in a 53-year-old woman. J Am Coll Cardiol 62:e525PubMedCrossRef
16.
Chou LY, Donohue WL (1952) Oxalosis; possible inborn error of metabolism with nephrolithiasis and nephrocalcinosis due to calcium oxalate as the predominating features. Pediatrics 10:660–666PubMed
17.
Brancaccio D, Poggi A, Ciccarelli C, Bellini F, Galmozzi C, Poletti I, Maggiore Q (1981) Bone changes in end-stage oxalosis. Am J Roentgenol 136:935–939CrossRef
18.
Meredith TA, Wright JD, Gammon JA, Fellner SK, Warshaw BL, Maio M (1984) Ocular involvement in primary hyperoxaluria. Arch Ophthalmol 102:584–587PubMedCrossRef
19.
20.
Broyer M, Brunner FP, Brynger H, Dykes SR, Ehrich JH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G (1990) Kidney transplantation in primary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant 5:332–336PubMedCrossRef
21.
Godwin JT, Fowler MF, Dempsey EF, Henneman PH (1958) Primary hyperoxaluria and oxalosis; report of a case and review of the literature. N Engl J Med 259:1099–1103PubMedCrossRef
22.
23.
Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker-Cohen R, Weismann I, Wanders RJ, Rumsby G, Roels F, Mandel H (2005) Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol 25:269–275PubMedCrossRef
24.
Takayama T, Nagata M, Ichiyama A, Ozono S (2005) Primary hyperoxaluria type 1 in Japan. Am J Nephrol 25:297–302PubMedCrossRef
25.
Williams HE, Smith LH Jr (1968) L-glyceric aciduria. A new genetic variant of primary hyperoxaluria. N Engl J Med 278:233–238PubMedCrossRef
26.
Chlebeck PT, Milliner DS, Smith LH (1994) Long-term prognosis in primary hyperoxaluria type II (L-glyceric aciduria). Am J Kidney Dis 23:255–259PubMedCrossRef
27.
Hicks NR, Cranston DW, Charlton CA (1983) Fifteen-year follow-up of hyperoxaluria type II. N Engl J Med 309:796PubMed
28.
Marangella M, Petrarulo M, Cosseddu D (1994) End-stage renal failure in primary hyperoxaluria type 2. N Engl J Med 330:1690PubMedCrossRef
29.
Naderi G, Latif A, Tabassomi F, Esfahani ST (2014) Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr Transplant 18:E69–73PubMedCrossRef
30.
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392–399PubMedCentralPubMedCrossRef
31.
Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21:162–172PubMedCentralPubMedCrossRef
32.
Belostotsky R, Pitt JJ, Frishberg Y (2012) Primary hyperoxaluria type III-a model for studying perturbations in glyoxylate metabolism. J Mol Med 90:1497–1504PubMedCrossRef
33.
Shih VE (2003) Amino acid analysis. In: Blau N, Duran M, Blaskovics ME, Gibson KM (eds) Physician’s guide to the laboratory diagnosis of metabolic diseases, 2nd edn. Springer, Berlin, pp 11–26CrossRef
34.
Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y (2014) 4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD Rep. doi:10.​1007/​8904_​2013_​291
35.
Hoppe B, Latta K, von Schnakenburg C, Kemper MJ (2005) Primary hyperoxaluria-the German experience. Am J Nephrol 25:276–281PubMedCrossRef
36.
Cochat P, Exanthus J, Basmaison O (1999) Fifth workshop on primary hyperoxaluria. Nephrol Dial Transplant 14:2784–2789CrossRef
37.
Al-Eisa AA, Samhan M, Naseef M (2004) End-stage renal disease in Kuwaiti children: an 8-year experience. Transplant Proc 36:1788–1791PubMedCrossRef
38.
Kamoun A, Lakhoua R (1996) End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. Pediatr Nephrol 10:479–482PubMedCrossRef
39.
Hattori S, Yosioka K, Honda M, Ito H (2002) The 1998 report of the Japanese national registry data on pediatric end-stage renal disease patients. Pediatr Nephrol 17:456–461PubMedCrossRef
40.
41.
Abumwais JQ (2012) Etiology of chronic renal failure in Jenin district, Palestine. Saudi J Kidney Dis Transpl 23:158–160PubMed
42.
Milliner DS, Wilson DM, Smith LH (2001) Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 59:31–36PubMedCrossRef
43.
Johnson SA, Rumsby G, Cregeen D, Hulton SA (2002) Primary hyperoxaluria type 2 in children. Pediatr Nephrol 17:597–601PubMedCrossRef
44.
Takayama T, Nagata M, Ozono S, Nonomura K, Cramer SD (2007) A novel mutation in the GRHPR gene in a Japanese patient with primary hyperoxaluria type 2. Nephrol Dial Transplant 22:2371–2374PubMedCentralPubMedCrossRef
45.
46.
Hopp K, Cogal AG, Hakonarson H, Milliner DS, Harris PC (2013) Estimated incidence of primary hyperoxaluria using population allele frequencies of disease variants [Abstract]. J Am Soc Nephrol 24:529ACrossRef
47.
Purdue PE, Lumb MJ, Fox M, Griffo G, Hamon-Benais C, Povev S, Danpure CJ (1991) Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 10:34–42PubMedCrossRef
48.
49.
Williams E, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E, Waterham H, Rumsby G (2009) Primary hyperoxaluria type 1: update and additional mutation analysis of the agxt gene. Hum Mutat 30:910–917PubMedCrossRef
50.
Lumb MJ, Danpure CJ (2000) Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem 275:36415–36422PubMedCrossRef
51.
Purdue PE, Takada Y, Danpure CJ (1990) Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 111:2341–2351PubMedCrossRef
52.
Purdue PE, Allsop J, Isaya G, Rosenberg LE, Danpure CJ (1991) Mistargeting of peroxisomal L-alanine:glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation. Proc Natl Acad Sci U S A 88:10900–10904PubMedCentralPubMedCrossRef
53.
Rinat C, Wanders RJ, Drukker A, Halle D, Frishberg Y (1999) Primary hyperoxaluria type I: a model for multiple mutations in a monogenic disease within a distinct ethnic group. J Am Soc Nephrol 10:2352–2358PubMed
54.
Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernández D, Salido E (2006) Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: single-center experience. Kidney Int 70:1115–1119PubMedCrossRef
55.
Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709PubMedCrossRef
56.
van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR (2004) Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 66:746–752PubMedCrossRef
57.
Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP (1999) The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 8:2063–2069PubMedCrossRef
58.
Rumsby G, Cregeen DP (1999) Identification and expression of a cDNA for human hydroxypyruvate/glyoxylate reductase. Biochim Biophys Acta 1446:383–388PubMedCrossRef
59.
Cregeen DP, Williams EL, Hulton S, Rumsby G (2003) Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 22:947CrossRef
60.
61.
Webster KE, Ferree PM, Holmes RP, Cramer SD (2000) Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 107:176–185PubMedCrossRef
62.
Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedCentralPubMedCrossRef
63.
Abratt VR, Reid SJ (2010) Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease. Adv Appl Microbiol 72:63–87PubMedCrossRef
64.
Birdsey GM, Lewin B, Holbrook JD, Simpson VR, Cunningham AA, Danpure CJ (2005) A comparative analysis of the evolutionary relationship between diet and enzyme targeting in bats, marsupials and other mammals. Proc Biol Sci 272:833–840PubMedCentralPubMedCrossRef
65.
Danpure CJ, Jennings PR (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 201:20–24PubMedCrossRef
66.
Danpure CJ, Cooper PJ, Wise PJ, Jennings PR (1989) An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol 108:1345–1352PubMedCrossRef
67.
Williams EL, Bockenhauer D, van't Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 27:3191–3195PubMedCrossRef
68.
Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT (2012) 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 1822:1544–1552PubMedCentralPubMedCrossRef
69.
Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736PubMedCrossRef
70.
Milliner DS (2005) The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 25:154–160PubMedCrossRef
71.
Daudon M, Jungers P, Bazin D (2008) Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med 359:100–102PubMedCrossRef
72.
73.
Leumann E, Hoppe B, Neuhaus T, Blau N (1995) Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 10(Suppl 8):14–16PubMedCrossRef
74.
Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155:839–843PubMedCrossRef
75.
Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783PubMedCrossRef
76.
Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 9:468–477PubMedCentralPubMedCrossRef
77.
Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ (1983) Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 309:445–448PubMedCrossRef
78.
Sikora P, von Unruh GE, Beck B, Feldkötter M, Zajaczkowska M, Hesse A, Hoppe B (2008) [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 73:1181–1186PubMedCrossRef
79.
Al-Abadi E, Hulton SA (2013) Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis-still the first choice? Pediatr Nephrol 28:1085–1089PubMedCrossRef
80.
Xue YQ, He DL, Chen XF, Li X, Zeng J, Wang XY (2009) Shock wave induced kidney injury promotes calcium oxalate deposition. J Urol 182:762–765PubMedCrossRef
81.
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H (2006) Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70:1305–1311PubMedCrossRef
82.
Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB (2011) Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 58:453–455PubMedCrossRef
83.
Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26:3609–3615PubMedCrossRef
84.
Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, Brodehl J (1996) Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 10:488–492PubMedCrossRef
85.
Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648PubMedCrossRef
86.
Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO (2003) One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 76:1458–1463PubMedCrossRef
87.
Jamieson NV, European PHI Transplantation Study Group (2005) A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984–2004. Am J Nephrol 39:282–289CrossRef
88.
Watts RW, Calne RY, Williams R, Mansell MA, Veall N, Purkiss P, Rolles K (1985) Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation. Q J Med 57:697–703PubMed
89.
Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU (2002) Renal allograft survival in patients with oxalosis. Transplantation 74:707–710PubMedCrossRef
90.
Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501PubMedCentralPubMedCrossRef
91.
Kasiske BL, Zeier MG, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Chapman JR, Vincenti FG, Balk EM, Wagner M, Raman G, Earley A, Abariga S, Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–155
92.
Harps E, Brinkert F, Ganschow R, Briem-Richter A, van Husen M, Schmidtke S, Herden U, Nashan B, Fischer L, Kemper MJ (2011) Immediate postoperative intensive care treatment of pediatric combined liver-kidney transplantation: outcome and prognostic factors. Transplantation 91:1127–1131PubMedCrossRef
93.
Ruder H, Otto G, Schutgens RB, Querfeld U, Wanders RJ, Herzog KH, Wölfel P, Pomer S, Schärer K, Rose GA (1990) Excessive urinary oxalate excretion after combined renal and hepatic transplantation for correction of hyperoxaluria type 1. Eur J Pediatr 150:56–58PubMedCrossRef
94.
Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438PubMedCentralPubMedCrossRef
95.
Nolkemper D, Kemper MJ, Burdelski M, Vaismann I, Rogiers X, Broelsch CE, Ganschow R, Müller-Wiefel DE (2000) Long-term results of pre-emptive liver transplantation in primary hyperoxaluria type 1. Pediatr Transplant 4:177–181PubMedCrossRef
96.
Shapiro R, Weismann I, Mandel H, Eisenstein B, Ben-Ari Z, Bar-Nathan N, Zehavi I, Dinari G, Mor E (2001) Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation 72:428–432PubMedCrossRef
97.
Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, Solomonov E, Rahamimov R, Braun M (2013) Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 19:646–648PubMedCrossRef
98.
Lam CW, Yuen YP, Lai CK, Tong SF, Lau LK, Tong KL, Chan YW (2001) Novel mutation in the GRHPR gene in a Chinese patient with primary hyperoxaluria type 2 requiring renal transplantation from a living related donor. Am J Kidney Dis 38:1307–1310PubMedCrossRef
99.
Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber F, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B (2012) Liver cell transplantation in severe infantile oxalosis-a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 27:2984–2989PubMedCrossRef
100.
Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A (2011) Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther 19:870–875PubMedCentralPubMedCrossRef
101.
Santana A, Salido E, Torres A, Shapiro LJ (2003) Primary hyperoxaluria type 1 in the Canary islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci 100:7277–7282PubMedCentralPubMedCrossRef
102.
Mesa-Torres N, Fabelo-Rosa I, Riverol D, Yunta C, Albert A, Salido E, Pey AL (2013) The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I. PLoS One 8:e71963PubMedCentralPubMedCrossRef
103.
Cellini B, Montioli R, Oppici E, Astegno A, Voltattorni CB (2014) The chaperone role of the pyridoxal 5′-phosphate and its implications for rare diseases involving B6-dependent enzymes. Clin Biochem 47:158–165PubMedCrossRef
104.
Salido E, Pey AL, Rodriguez R, Lorenzo V (2012) Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta 1822:1453–1464PubMedCrossRef
105.
Frishberg Y, Zeharia A, Lyakhovetsky R, Bargal R, Belostotsky R (2014) Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 51:526–529PubMedCrossRef
Metadaten
Titel
Primary hyperoxalurias: diagnosis and treatment
verfasst von
Efrat Ben-Shalom
Yaacov Frishberg
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 10/2015
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-014-3030-1

Weitere Artikel der Ausgabe 10/2015

Pediatric Nephrology 10/2015 Zur Ausgabe

Original Article

Towards a biomarker panel for the assessment of AKI in children receiving intensive care

Educational Review

Tuberous sclerosis complex: the past and the future

Educational Review

Recurrent focal segmental glomerulosclerosis after kidney transplantation

Brief Report

Proteinuria caused by glomerular hypertension during adolescence associated with extremely premature birth: a report of two cases

Original Article

Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis

Original Article

Renal formulas pretreated with medications alters the nutrient profile

Neu im Fachgebiet Pädiatrie

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise